Associated Genetic Biomarkers
Cyclin B3 (CCNB3) is a gene that encodes a member of the cyclin family that functions as a regulator of cyclin-dependent kinases (CDKs). Cyclin B3 is involved in the regulation of the cell cycle. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, lung cancer, and skin cancer.
CCNB3 is altered in 0.03% of all cancers with lung adenocarcinoma, round cell sarcoma, acute myeloid leukemia, breast invasive lobular carcinoma, and cancer of unknown primary having the greatest prevalence of alterations .
The most common alteration in CCNB3 is CCNB3-BCOR Fusion (0.00%) .
CCNB3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CCNB3 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CCNB3 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CCNB3 Mutation .
Abemaciclib is the most frequent therapy in trials with CCNB3 as an inclusion criteria .
Significance of CCNB3 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.